Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC — StellaPhase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(16 sites)
China
Beijing Friendship Hospital, Capital Medical University, Beijing Chongqing University Three Gorges Hospital, Chongqing The First People's Hospital of Foshan, Foshan Fujian Medical University Union Hospital, Fuzhou Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou Nanfang Hospital Southern Medical University, Guangzhou Guangdong Provincial People's Hospital, Guanzhou The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou The First Affiliated Hospital of USTC Anhui Provincial Hospital, Hefei The Affiliated Hospital of Inner Mongolia Hospital, Hohhot The Affiliated Hospital of Qingdao University, Qingdao Zhongshan Hospital Fudan University, Shanghai Shenzhen People's Hospital, Shenzhen Tongji Hospital Tongji College of HUST, Wuhan The First Affiliated Hospital of Xiamen University, Xiamen Zhongshan City People's Hospital, Zhongshan Last updated September 2022